Niagen Bioscience, Inc.
NAGE
$10.04
$0.010.10%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 35.89% | 29.77% | 19.18% | 9.95% | 5.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 35.89% | 29.77% | 19.18% | 9.95% | 5.74% |
| Cost of Revenue | 26.19% | 24.70% | 15.92% | 5.46% | 2.09% |
| Gross Profit | 42.15% | 33.01% | 21.28% | 12.97% | 8.23% |
| SG&A Expenses | 6.90% | -0.34% | -6.96% | -3.17% | -6.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.37% | 8.19% | 3.03% | 1.08% | -2.06% |
| Operating Income | 824.15% | 403.28% | 237.99% | 106.50% | 73.82% |
| Income Before Tax | 1,455.77% | 513.21% | 279.32% | 122.95% | 79.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1,411.32% | 499.80% | 273.15% | 122.95% | 79.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1,411.32% | 499.80% | 273.15% | 122.95% | 79.19% |
| EBIT | 824.15% | 403.28% | 237.99% | 106.50% | 73.82% |
| EBITDA | 1,354.64% | 513.99% | 286.83% | 122.21% | 81.96% |
| EPS Basic | 1,370.00% | 489.15% | 268.89% | 122.52% | 79.59% |
| Normalized Basic EPS | 1,407.08% | 500.34% | 274.33% | 122.32% | 84.79% |
| EPS Diluted | 997.39% | 414.77% | 241.06% | 110.89% | 74.89% |
| Normalized Diluted EPS | 1,328.32% | 478.31% | 265.13% | 121.77% | 84.79% |
| Average Basic Shares Outstanding | 3.00% | 1.97% | 1.26% | 1.07% | 3.07% |
| Average Diluted Shares Outstanding | 9.29% | 5.95% | 3.43% | 1.67% | 3.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |